Announcements Trials
Browse Landscape

Phase

Phase 2 59Phase 1/2 11Phase 1 6Phase 3 4Phase NA 3Phase 4 3Phase 2/3 2

Status

Recruiting 6Not yet recruiting 3Unknown 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × 130-nm albumin-bound paclitaxel × Clear all
NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Tianjin Medical University Cancer Institute and Hospital

Phase 2/3 Unknown
420 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04435652 2020-06-17

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
492 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡